---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-215752"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2026-05-11T23:59:59+00:00"
generated_at: "2026-05-14T19:22:08.614619+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed

## Summary
- Total net revenue $34.7M vs $38.9M YoY; Acute Care franchise up 32% led by ZYNRELEF (+27%) and APONVIE (+50%).
- Oncology net revenue $21.1M (-26.3% YoY) as CINVANTI declined 20.2% and SUSTOL wind-down continued.
- Reaffirmed FY2026 guidance: net revenue $173-183M and Adjusted EBITDA $10-20M; cash $44.8M.
- Settled CINVANTI patent litigation with Baxter; case dismissed April 28, 2026.
- Sales force expansion on track for Q3 2026; ZYNRELEF prefilled syringe program on schedule with stability data in Q1 2027.

## SEC filing metadata
- accession: 0001193125-26-215752
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2026-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/0001193125-26-215752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/hrtx-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-215752
- JSON: https://secwatch.observer/filing/0001193125-26-215752.json
- Plain text: https://secwatch.observer/filing/0001193125-26-215752.txt

## Source-grounded claims
- claim_id: d95ad0384e7a867f1c875a71782ff0593c0225ed
  claim: HERON THERAPEUTICS, INC. /DE/ reported the three months ended March 31, 2026 results: revenue $34.7 million. Guidance reaffirmed.
  evidence_excerpt: Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/0001193125-26-215752-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.